Clinical trial
A Phase IIa, Placebo-controlled, Double Blind, Randomised Multicentre Pilot Study to Investigate the Efficacy, Safety and Tolerability of the Monoclonal Antibody ATH3G10 in Patients With ST-elevation Myocardial Infarction
NCT03991143 is registered in ClinicalTrials.gov with Athera Biotechnologies AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Placebo-controlled, Double Blind, Randomised Multicentre Pilot Study to Investigate the Efficacy, Safety and Tolerability of the Monoclonal Antibody ATH3G10 in Patients With ST-elevation Myocardial Infarction
- Lead sponsor
- Athera Biotechnologies AB
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 29, 2019
- Completion date
- April 19, 2021
- Enrollment
- 82 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.